Peroxisome proliferator-activated receptor alpha (PPAR-α), also known as NR1C1 (nuclear receptor subfamily 1, group C, member 1), is a nuclear receptor protein functioning as a transcription factor that in humans is encoded by the PPARA gene. PPAR-α is a transcription factor regulated by free fatty acids, and is a major regulator of lipid metabolism in the liver. PPAR-alpha is activated under conditions of energy deprivation and is necessary for the process of ketogenesis, a key adaptive response to prolonged fasting. Mechanism of action (MOA) of PPAR Alpha Agonist forms a heterodimeric complex with another nuclear receptor called retinoid X receptor (RXR). This complex is then translocated into the nucleus and in the nucleus, the PPAR-alpha/RXR complex binds to specific DNA sequences called PPREs in the promoter regions of target genes. PPREs are typically located upstream of genes involved in lipid metabolism, such as those related to fatty acid oxidation, lipid transport, and inflammation. PPAR Alpha Agonist is used in the treatment of endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, digestive system diseases, hyperinsulinism, heart diseases, hypertension, liver diseases, blood coagulation disorder, brain diseases, etc. The rising prevalence of endocrine diseases, diabetes mellitus, and an aging population are the key drivers for PPAR Alpha Agonist market. For instance, according to the World Health Organization 2023, About 422 million people worldwide have diabetes. Moreover, the development of novel molecules by market players is coming up to overcome challenges in therapy. For instance, Roche’s Aleglitazar (R1439) for the treatment of diabetes mellitus is under the various stages of clinical studies.
Key Market Developments:
- In September 2022, according to the Taylor and Francis Journal research findings, modified fenofibrate pellets developed showed enhanced bioavailability and delayed-release properties.
Drugs under the Pipeline for PPAR Alpha Agonist:
- Duvie (Lobeglitazone)
- Aleglitazar (R1439)
- Elafibranor (GFT505)
- Parmodia (Pemafibrate)
- Lipaglyn (Saroglitazar)
- Cholib (Fenofibrate
- Gemcabene (CI-1027)
- Bilessglu (Chiglitazar)
- Lanifibranor (IVA337)
- ABTL0812
- Atorvastatin/Fenofibrate (CKD-337)
- Indeglitazar (PLX204)
- Pemafibrate ER (K-877-ER)
- Cetaxin (Ciprofibrat)
- Ciprol (Ciprofibrate)
- Triglide (Fenofibrate)
- Micro-Palmitoylethanolamide (FSD 201)
- Livasupril (Micronized Fenofibrate/Pitavastatin)
- OMT-28
- Fenocid (Fenofibric Acid)
- Pemafibrate
- DSP-8658
- PLX 200
- SYO 0805
- ZYH7
Clinical Activity and Developments of PPAR Alpha Agonist:
Till July 2023, more than 25 companies have approximately 31 molecules targeting the many endocrine disorders and diabetes mellitus. For these molecules, more than 78 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,
- In November 2021, Roche has completed the phase 2, randomized, double-blind, study to evaluate the effect of Aleglitazar (R1439) on glycemic control in patients with type 2 diabetes mellitus.
- In May 2023, Ipsen completed phase 1, single-center, open-label, repeat-dose study to evaluate the pharmacokinetics, safety, and tolerability of Elafibranor (GFT505) in healthy Japanese and non-Asian participants.
|
Molecule Name |
Number of Studies |
|
Duvie (Lobeglitazone) |
42 |
|
Aleglitazar (R1439) |
22 |
|
Elafibranor (GFT505) |
23 |
|
Parmodia (Pemafibrate) |
18 |
|
Lipaglyn (Saroglitazar) |
17 |
Target Indication Analysis of PPAR Alpha Agonist
Molecules such as Aleglitazar (R1439) are under development by Roche for the line of treatment for the treatment of cardiovascular disorders, and type 2 diabetes mellitus. Moreover, Zydus Lifesciences Lipaglyn (Saroglitazar) for the potential treatment of dyslipidaemias, hypertriglyceridemia, type 2 diabetes mellitus, liver disorders, and polycystic ovary syndrome is under various stages of clinical trials. Ipsen’s Elafibranor (GFT505) for the indication of Primary sclerosing cholangitis in phase 2 and biliary cirrhosis in phase 3 clinical trial. Many other molecules is under clinical development for diabetes mellitus, acute coronary syndrome and many endocrine diseases.
Regional Analysis
PPAR Alpha Agonist Market
PPAR Alpha Agonists have been identified as potential therapeutic candidates for endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, etc. The increased incidence of various metabolic diseases like lipid, glucose metabolism disorders, type-1 diabetes mellitus, and rising old age population; Seems to create an opportunity for the future and burgeon the growth of the PPAR Alpha Agonist market. For instance, according to the International Diabetes Federation 2021, around 206 million people in the Western Pacific and 90 million people in Southeast Asia are living with diabetes globally. Moreover, with increased R&D activity and government reimbursement policies, modern diagnostic centers are expected to create lucrative opportunities for the PPAR Alpha Agonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
The indication of Aleglitazar (R1439) is the treatment of cardiovascular disorders, type 2 diabetes mellitus, etc.
Major market players include Ipsen, Chong Kun Dang, Roche, Zydus Lifesci, Daiichi Sankyo, etc are a few leading market players.
Major Indications for PPAR Alpha Agonists are used to treat endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, digestive system diseases, etc.
There are a total of 25 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
- Chong Kun Dang
- Roche
- Ipsen
- Kowa
- Zydus Lifesci
- NeuroBo
- Chipscreen
- Inventiva
- Ability Pharma
- Daiichi Sankyo
- Pfizer
- Sanofi
- Vectura
- Shionogi
- FSD Pharma
- Sumitomo Pharma
- Polaryx
- Samyang Group
- Zydus Cadila